ViewRay Inc., a Cleveland, Ohio-based medical device company, has closed a $45m round of Series C venture capital financing.
Backers include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital (SVC) GmbH.
The company intends to use the funding to prepare for market launch. The first research system is undergoing final installation at the Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri.
Led by President and CEO Gregory M. Ayers, MD, PhD., ViewRay develops image-guided radiation therapy technology for the treatment of cancer. It is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.
The company’s treatment planning and delivery software received 510(k) premarket notification clearance from the U.S. FDA in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review.